Personalized Oncogenomics (POG) Program of British Columbia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorBritish Columbia Cancer Agency
About this trial
The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer "drivers" and corresponding drugs that may inhibit these pathways.
Eligibility criteria
Qualifiers
Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses.
Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR if there is adequate archival material available, either fresh frozen or FFPE (if specimen is thought to be adequate) that is taken after the most recent chemo or radiation. Ideally this sample should have been collected within 16 weeks of the date of consent. If archival tissue is not adequate and if a biopsy is not feasible or deemed medically safe by the investigators the patient would become ineligible.
Patients must understand and agree to provide a blood test (or other sample of normal DNA) for germline genomic analysis.
ECOG PS 0 or 1.
Disqualifiers
Unable or unwilling to consent to the above tissue and blood requirements.
Significant medical condition that in the opinion of the treating or consenting oncologist and/or the POG central office review team renders the subject not suitable for participation. This includes the likelihood that a subject would be suitable for a clinical trial within 12 weeks after POG biopsy.
Unwilling or unable to provide treatment and outcome follow up information to the BC Cancer or affiliated investigators.
Unwilling to receive medically actionable findings (germline and/or somatic).
Trial design
Treatments tested in this trial
- Genome sequencing
Treatment groups
5,000 Participants
are divided into 1 treatment groupSponsors and collaborators
British Columbia Cancer Agency
Lead sponsor
BC Cancer Foundation
Collaborator
Source ClinicalTrials.gov